Each October, the Nobel Committee invites the world to pause and ask which discoveries have most altered the human condition — and in 2026, the medicine prize opens that reckoning with a question about hunger itself. Research into GLP-1 and the hormones that govern appetite has quietly moved from laboratory notebooks into the daily lives of millions, reshaping how medicine understands and treats obesity. The announcement, expected Monday morning in Stockholm, may name the scientists whose foundational work made that transformation possible — though the committee, as ever, reserves the right to
Weight-loss drug research tipped for Nobel medicine prize as 2026 award season opens
Enormous worldwide clinical impact
Mark
So the medicine prize is basically a referendum on obesity drugs?
Mimi
Not quite—it's about the foundational science that made those drugs possible. The research into GLP-1 and other appetite hormones happened decades before Ozempic existed. The Nobel recognizes the discovery, not the commercial product.
Luke
But the timing is interesting, right? These drugs are everywhere now. Is the committee rewarding the science, or responding to the cultural moment?
Mimi
That's a fair question. Pendlebury says GLP-1 gets the top spot because of its "enormous worldwide clinical impact." That's both scientific merit and real-world consequence.
Mark
Who are the actual people who might win?
Mimi
Three names keep coming up: Daniel Drucker from Canada, Jens Juul Holst from Denmark, and Svetlana Mojsov, who was born in Yugoslavia and works in America. Each contributed essential pieces.
Luke
Do we know what they actually discovered, or are we just told they're contenders?
Mimi
The source names them as leaders in the field but doesn't detail their specific discoveries. It's more about pattern recognition—these three are consistently mentioned by Nobel watchers.
Mark
What if it's not about weight loss at all?
Mimi
The committee could go in several directions. Stem cell research on skin, a new imaging technique for the eye, immune system receptors. The medicine prize is broad.
Luke
So we're really just speculating until Monday?
Mimi
Yes. Clarivate uses citation data to predict, but the committee's actual reasoning stays private until after the announcement.
Der Puls
- The global explosion of weight-loss drugs like Ozempic has built enormous anticipation around GLP-1 hormone research, making it the year's most-watched Nobel contender.
- Three scientists — Daniel Drucker, Jens Juul Holst, and Svetlana Mojsov — stand at the center of speculation, their decades of foundational work now carrying the weight of a possible Nobel.
- The committee could pivot entirely, with rival fields — skin regeneration, retinal imaging, and immune cell adhesion — each representing legitimate and consequential scientific breakthroughs.
- Beyond medicine, the week's prize announcements carry their own tensions: a literature prize that may break toward Latin America, and a peace prize still shadowed by last year's politically charged selection.
- The Nobel season, unfolding prize by prize through October 12, functions as a kind of annual audit of human progress — and this year, the opening question is whether science has finally found a way to govern hunger.
Each October, the Nobel Committee invites the world to pause and ask which discoveries have most altered the human condition — and in 2026, the medicine prize opens that reckoning with a question about hunger itself. Research into GLP-1 and the hormones that govern appetite has quietly moved from laboratory notebooks into the daily lives of millions, reshaping how medicine understands and treats obesity. The announcement, expected Monday morning in Stockholm, may name the scientists whose foundational work made that transformation possible — though the committee, as ever, reserves the right to surprise.
The 2026 Nobel Prize season begins Monday with the medicine award, and anticipation has gathered around one field above all others: the hormonal science behind drugs like Ozempic and Mounjaro. Research into GLP-1 — a molecule released by the intestine after eating that signals the brain a person is full — has moved from obscure biochemistry into one of the most consequential medical developments of the era. David Pendlebury of Clarivate, who tracks Nobel prospects through citation patterns, calls it the top contender, citing its "enormous worldwide clinical impact."
Three scientists are most frequently named as potential laureates: Canadian endocrinologist Daniel Drucker, Danish physician Jens Juul Holst, and Yugoslav-born American chemist Svetlana Mojsov — each of whom made foundational contributions to understanding how appetite-regulating hormones work and how they might be turned into therapies. Related work on leptin, ghrelin, and the microbiome's metabolic role also figures in the conversation.
The committee, however, may choose differently. Stem cell research on skin regeneration by Elaine Fuchs and Fiona Watt, optical coherence tomography's revolution in retinal imaging, and Timothy Springer's discoveries about immune cell adhesion receptors all represent serious alternatives — each with its own claim on transformative impact.
The medicine prize is only the opening act. Physics follows Tuesday, chemistry Wednesday, and literature Thursday — where speculation centers on whether the Swedish Academy might honor a woman writer from Latin America, with Samanta Schweblin among those mentioned. The peace prize on Friday, awarded in Oslo, arrives under particular scrutiny after last year's controversial selection, with possible honorees including Ukrainian child-rights activist Mykola Kuleba, Sudan's Emergency Response Rooms, and the Committee to Protect Journalists. The economics prize closes the season on October 12.
The 2026 Nobel Prize season opens Monday with the medicine award, and the smart money is on research into the hormones that control hunger and fullness—the scientific foundation for drugs like Ozempic and Mounjaro that have reshaped obesity treatment worldwide.
The Nobel Committee will announce its choice at 11:30 am Central European Time. Over the next week, six prizes will be revealed daily: medicine, physics, chemistry, literature, peace, and economics. But the medicine prize carries particular weight this year because it sits at the intersection of basic science and a global health transformation. The research being discussed—work on appetite-regulating hormones, particularly a molecule called GLP-1—has moved from laboratory discovery into the hands of millions of patients seeking to lose weight.
David Pendlebury, who leads research analysis at Clarivate, a firm that forecasts Nobel winners by tracking citation patterns in scientific literature, puts GLP-1 research at the top of his list. "I would put GLP-1 at the top of the list, just because of its enormous worldwide clinical impact," he said. The hormone, released by the intestine after eating, signals the brain that the body is full. Drugs designed to mimic GLP-1 have become some of the most sought-after medications in the world. Other contenders in the appetite-regulation field include research on leptin and ghrelin, two hormones that regulate satiety and hunger, and work on the microbiome's role in metabolic control.
Three scientists appear regularly in Nobel speculation for this body of work: Daniel Drucker, a Canadian endocrinologist; Jens Juul Holst, a Danish physician; and Svetlana Mojsov, a Yugoslav-born American chemist. Each made foundational contributions to understanding how these hormones work and how they might be harnessed therapeutically.
But the medicine committee could move in other directions entirely. Stem cell research into skin regeneration and wound healing, led by American cell biologist Elaine Fuchs and British researcher Fiona Watt, represents another strong possibility. A newer imaging technique called optical coherence tomography—which uses reflected light to create detailed cross-sectional images of biological tissues, particularly in the eye—could also be honored. The technology has given doctors the ability to detect and monitor diseases of the retina and optic nerve with unprecedented precision. Research into adhesion receptors in the immune system, identified by immunologist Timothy Springer, offers yet another path. These molecular structures act as grips on immune cells, helping them attach to blood vessels and reach infected tissue. Understanding them has opened new avenues for treating inflammatory and autoimmune diseases.
The medicine prize announcement kicks off a week of revelations. Physics comes Tuesday, chemistry Wednesday. The literature prize on Thursday has literary critics speculating about whether the Swedish Academy might select a woman writer, possibly from Latin America, following last year's award to Hungarian author Laszlo Krasznahorkai. Argentine writer Samanta Schweblin, 48, is among those mentioned, along with Jamaica Kincaid, Can Xue, Gerald Murnane, Alexis Wright, Thomas Pynchon, and Cristina Rivera Garza.
The peace prize on Friday—the only Nobel awarded in Oslo rather than Stockholm—carries particular weight this year. Last year's award to Venezuelan opposition leader Maria Corina Machado sparked controversy, and the committee is aware that the choice will be scrutinized closely. Kristian Berg Harpviken, secretary of the Nobel Committee, acknowledged the pressure: "There's always a lot of lobbying, and ultimately perhaps also attempts to exert pressure on the committee. We're very used to that." Possible laureates include a joint award to Save the Children and Mykola Kuleba, a Ukrainian activist fighting for the return of children illegally taken to Russia; Sudan's Emergency Response Rooms, a volunteer network operating amid war and famine; and the Committee to Protect Journalists, after 2025 became the deadliest year on record for the profession. The economics prize concludes the season on October 12.
Bemerkenswerte Zitate
I would put GLP-1 at the top of the list, just because of its enormous worldwide clinical impact.— David Pendlebury, Clarivate
There's always a lot of lobbying, and ultimately perhaps also attempts to exert pressure on the committee. We're very used to that.— Kristian Berg Harpviken, Nobel Committee secretary
Möchten Sie die ganze Geschichte?
Das Original lesen bei Yahoo News Singapore ↗